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Abstract
Background
Community mass treatment with 30mg/kg azithromycin is central to the newWHO strategy
for eradicating yaws. Both yaws and trachoma— which is earmarked for elimination by
2020 using a strategy that includes mass treatment with 20mg/kg azithromycin—are
endemic in the Pacific, raising the possibility of an integrated approach to disease control.
Community mass treatment with azithromycin for trachoma elimination was conducted in
the Solomon Islands in 2014.
Methods
We conducted a study to assess the impact of mass treatment with 20mg/kg azithromycin
on yaws. We examined children aged 5-14 years and took blood and lesion samples for
yaws diagnosis.
Results
We recruited 897 children, 6 months after mass treatment. There were no cases of active
yaws. Serological evidence of current infection was found in 3.6% (95% CI= 2.5-5.0%). This
differed significantly between individuals who had and had not received azithromycin (2.8%
vs 6.5%, p=0.015); the prevalence of positive serology in 5-14 year-olds had been 21.7%
(95% CI=14.6%-30.9%) 6 months prior to mass treatment. Not receiving azithromycin was
associated with an odds of 3.9 for infection (p=0.001). National figures showed a 57%
reduction in reported cases of yaws following mass treatment.
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Discussion
Following a single round of treatment we did not identify any cases of active yaws in a previ-
ously endemic population. We found a significant reduction in latent infection. Our data sup-
port expansion of the WHO eradication strategy and suggest an integrated approach to the
control of yaws and trachoma in the Pacific may be viable.
Author Summary
Yaws is a bacterial infection closely related to syphilis. The WHO has launched a world-
wide campaign to eradicate yaws by 2020. This strategy relies on mass treatment of the
whole community with the antibiotic azithromycin. Mass treatment with the same antibi-
otic is also recommended by WHO to treat the eye condition trachoma but the dose used
for this is lower. In this study we assessed the impact of a trachoma control programme in
the Solomon Islands on yaws. Following a single round of mass treatment the number of
yaws cases fell significantly compared to before treatment. We also saw fewer new cases of
yaws being reported to the Ministry of Health. Our findings suggest that mass treatment
with the lower dose of azithromycin is also effective as a treatment for yaws. In countries
where both yaws and trachoma are found it may be possible to develop an integrated strat-
egy for both conditions.
Introduction
Yaws, caused by Treponema pallidum subsp pertenue, is a non-venereal infection closely
related to syphilis that predominantly affects children living in remote, rural communities in
tropical countries[1]. Infection manifests as lesions of the skin, bone and cartilage and,
untreated, may progress to destructive tertiary lesions[2]. Yaws was once widespread through-
out the tropics. Previous yaws control efforts in the middle of the twentieth century were based
on treatment with injectable long-acting penicillin[3], and resulted in significant reductions in
the burden of disease worldwide[4]. Despite these initial successes, the disease subsequently
rebounded in a number of countries and it is currently thought to be endemic in at least 12
countries across West Africa, South East Asia and the Pacific[1].
In 2012, treatment with azithromycin was shown to be highly effective for yaws[5], and com-
munity mass treatment became the foundation of the newWHOMorges yaws eradication strat-
egy[6]. Azithromycin has a number of advantageous characteristics as a mass treatment agent,
including oral route of administration, long tissue half-life, and an acceptable side-effect profile.
Community mass treatment with azithromycin is also central to the control of trachoma[7],
but the recommended dose used in trachoma control (20mg/kg, max 1g) is lower than that rec-
ommended for yaws (30mg/kg, max 2g). The International Task Force for Disease Eradication
highlighted the need to investigate the effect of lower dose azithromycin for the treatment of
yaws, and the possibility of synergies with trachoma control programmes in countries where
the two diseases are co-endemic. In some areas of Ghana in which azithromycin mass drug
administration was previously used for trachoma control, yaws is currently undetectable[8],
supporting the hypothesis that lower dose azithromycin may be effective.
Unexpectedly, several recent studies have demonstrated thatHaemophilus ducreyi[9,10] is a
common cause of non-genital ulcerative skin lesions in children in yaws endemic communities.
This is a finding which can present difficulties for clinical case identification. Community
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perceptions of the value of mass treatment campaigns may be affected by the impact of azithro-
mycin on other common skin infections. Genital strains ofH. ducreyi are responsive to azithro-
mycin[11], so it is possible that mass treatment with azithromycin may have a synergistic
benefit on non-yaws ulcerative skin lesions in these communities.
Both yaws and trachoma are endemic in the Solomon Islands[12], which routinely reports
the third highest number of cases of yaws among all countries worldwide[13]. In 2014, the Sol-
omon Islands Ministry of Health and Medical Services (MHMS) undertook community mass
treatment with azithromycin as part of the SAFE strategy for trachoma elimination. We per-
formed a prospective study in the Western Province of the Solomon Islands to assess the
impact of azithromycin used against trachoma on the prevalence of active and latent yaws.
Methods
As previously described [12], in September and October 2013, we conducted a pre-mass treat-
ment survey in Western and Choiseul Provinces of the Solomon Islands, and documented a
high prevalence of active and latent yaws. In mid 2014, mass antibiotic treatment was under-
taken for trachoma by the Ministry of Health, in Western Province only, Choiseul Province
not qualifying for mass treatment on the basis of a lower prevalence of active trachoma. Azi-
thromycin was administered at 20mg/kg (max 1g) with dose determined by body weight, mea-
sured using analogue scales. Due to the death of a local religious leader in June 2014, some
communities in the province were in mourning and did not receive treatment with azithromy-
cin. For the purposes of this study, we randomly selected a subset of Western Province commu-
nities known to have received treatment with azithromycin. At each household, we collected
data on number of residents and whether no, some, or all members of the household had
received treatment with azithromycin as part of the mass treatment campaign for trachoma.
We enrolled children aged 5–14 years for assessment, collecting individual level data on age,
gender, the presence or absence of clinical signs and symptoms of yaws, yaws treatment his-
tory, and whether the individual reported having received treatment with azithromycin. We
categorized skin lesions using the WHO yaws pictorial guide[14]. All data were entered directly
into Android smartphones using the ODK software package[15].
Venepuncture was performed and a serum sample collected from each individual. In indi-
viduals with ulcerative or papillomatous skin lesions, we also collected a swab sample of lesion
exudate. Exudate was transferred to a FTA Elute Micro Card (GE Healthcare, Buckingham-
shire, UK) using three firm side-to-side passes of the swab across the card. We placed each
card in its own re-sealable plastic packet with a sachet of desiccant. All samples were trans-
ferred to the National Referral Hospital, Honiara, where they were frozen at -20°C, and shipped
on dry ice to the London School of Hygiene & Tropical Medicine (LSHTM), UK and the Cen-
ters for Disease Control and Prevention (CDC), USA for diagnostic testing.
Laboratory testing
Serum samples were tested at LSHTM with the Treponema pallidum particle agglutination test
(TPPA, Mast Diagnostics, Merseyside UK). On samples that were TPPA-positive, a quantita-
tive plasma reagin test (RPR, Deben Diagnostics, Ipswich, UK) was performed. Lesion swabs
were tested at the CDC using a multiplex real-time (RT) PCR for the identification of Trepo-
nema pallidum sub-species DNA[16]. If the T pallidum PCR was positive, we intended to use a
second multiplex RT PCR to detect mutations in the 23S rRNA gene associated with azithro-
mycin resistance. Regardless of the result of the T. pallidum PCR, we performed an additional
duplex RT PCR for the detection ofHaemophilus ducreyi andMycobacterium ulcerans DNA
[9]. All laboratory testing was performed by individuals masked to the clinical findings.
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Routine reporting of yaws incidence data
Suspected cases of yaws are reported via the MHMS Health Information System. We extracted
data on the number of cases of yaws seen, per month, across all clinics in the Western Province
of the Solomon Islands during the period 2011 to 2014 to allow an assessment of the impact of
community mass treatment on the incidence of disease presentation.
Statistical analysis
A positive TPPA was taken as evidence of previous or current infection. Individuals with clini-
cal signs of yaws, a positive TPPA and an RPR titre of1:4 (dual-seropositivity) were consid-
ered to have active yaws. Individuals without clinical signs of yaws and with a positive TPPA
and an RPR titre of1:4 were considered to have latent yaws. An RPR titre of1:16 was con-
sidered to be a high-titre positive. We classified household size as5 or>5 residents, 5 house-
holders being the national average according to the most recent census[17]. Household
treatment with azithromycin was categorized as complete, incomplete (at least 1 individual not
treated) or none. The prevalence of active and latent yaws was compared between individuals
who had and had not received treatment with azithromycin. Multivariable logistic regression
was used to estimate unadjusted and adjusted odds ratios (ORs) for factors associated with
both TPPA- and dual-seropositivity. Robust standard errors were used to calculate all confi-
dence intervals (CIs) and P values, to account for village-level clustering[18]. The impact of
mass treatment on cases reported to the MHMS was analysed by fitting a linear regression
model to the time series on incident yaws cases, controlling for known seasonal variations and
trend in yaws incidence. To account for autocorrelation, the error in the model was assumed to
follow an autoregressive process, with a lag of one. All analyses were performed using Stata
13.1 (Statacorp, Texas).
Sample size
Our pre-mass drug administration (MDA) survey had shown that the prevalence of dual-sero-
positivity in these communities was approximately 20%[12]. Assuming that treatment with azi-
thromycin is 90% effective, the prevalence in people who receive treatment would be
anticipated to be approximately 2% post treatment. The prevalence of yaws in untreated indi-
viduals was also predicted to fall due to reduced community transmission, although there were
no data to guide the likely magnitude of this effect. Assuming, conservatively, that prevalence
amongst untreated individuals would fall by 25%, 72 individuals receiving azithromycin and
72 individuals who did not receive azithromycin would have 90% power to detect a difference
in the prevalence of yaws. Given anticipated community coverage of 90%, a total survey sample
of 720 individuals would therefore be required.
Ethical approval
Written informed consent was obtained from each participating child’s parent or guardian by
a member of staff fluent in the local dialect. Assent was obtained from all children. Ethical
approval for the study was granted by the ethics committees of the Solomon Islands MHMS
and the LSHTM (6358).
Results
We enrolled 897 children from 441 households in 11 communities. The median age of children
was 9 years, and 466 (52%) were male. 717 children (80%) reported having been treated with
azithromycin as part of the trachoma control programme (Table 1) (S1 File).
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Two hundred and thirty seven children (26%) had a clinically apparent skin lesion. Twenty-
eight children (3.1%) had a skin lesion clinically consistent with yaws. Lesions were more com-
mon in individuals who had not received MDA, but this difference was not statistically signifi-
cant. (4.9% vs 2.6%, p = 0.101). No individual with a skin lesion consistent with active yaws had
dual-positive serology. Bone swelling consistent with secondary yaws was rare, occurring in
only 4 subjects (0.5%). Sixty children (6.7%) had skin lesions consistent with healed yaws. Other
skin lesions including ringworm and bacterial infections were common (158 children, 17.6%).
Two hundred and twenty eight children (25%, 95% CI 23–28%) had a positive TPPA. The
prevalence did not differ significantly between individuals who had and had not received treat-
ment with azithromycin (24% vs 26%, p = 0.598). Thirty two children (3.5%, 95% CI 2.5–4.9%)
had a positive TPPA and an RPR titre of 1:4; the prevalence of this differed significantly
between individuals who had and had not received treatment with azithromycin (2.8% vs 6.6%,
p = 0.015). 11 children (1.2%, 95% CI 0.06–2.2%) had a high titre positive RPR and this also
differed significantly between individuals who had and had not received azithromycin (0.8% vs
2.7%, p = 0.046) (Fig 1). We collected lesion swabs from twenty individuals. Swabs could not
be collected from eight ulcerative lesions as they were dry. No sample tested positive for T. p
subsp. pertenue, but 7 swabs (35%) were positive for H. ducreyi.
Given the small number of individuals with dual sero-positivity these subjects were com-
bined into a single group for the purpose of further analysis. People who had not taken azithro-
mycin had higher odds of dual sero-positivity than those who had (OR = 2.49, 95% CI 1.2–5.2,
p = 0.015), and after adjusting for confounding due to age, gender, and community of resi-
dence, the odds ratio was 3.8 (95% CI 1.8–8.5, p = 0.001) (Tables 2 and 3). Increasing age was
associated with TPPA positivity, but no other variable was associated with dual sero-positivity.
In the pre-mass treatment period (n = 36 months) the mean monthly number of cases of
yaws reported by clinicians in the Western Province was 184. In the interrupted time series
analysis, the number of cases was 183 in the dry season and 158 in the wet season (p = 0.440),
and mass treatment was followed by a reduction in the mean number of cases reported per
month of 101 case (relative reduction 57%, p = 0.044) (Fig 2).
Discussion
In this study, a single round of community mass treatment with 20mg/kg azithromycin, given
for trachoma elimination, resulted in a significant reduction in the prevalence of both active
and latent yaws, from 1.5% and 20.2% pre-treatment[12], to 0.0% and 3.6% post-treatment
(p = 0.002 and<0.001, respectively). The prevalence of infection declined both in individuals
who had received treatment and in those who had not, suggesting that a single round of
Table 1. Demographics of study subjects.
Number of children 897
Number of households 441
Household size (Median, IQR) 6 (4–7)
Household MDA Coverage Complete 59%
Incomplete 28%
None 13%
Age (Median, IQR) 9 (7–12)
Male 466 (52%)
Received treatment with azithromycin 717 (80%)
Reported treatment for yaws in last year 93 (10%)
doi:10.1371/journal.pntd.0003988.t001
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treatment may have reduced transmission, resulting in a population level benefit that extended
to individuals who were not themselves treated. Consistent with this, the impact of azithromy-
cin appeared particularly marked in reducing the prevalence of high-titre positive individuals,
who are thought to drive transmission at community level. Our results are mirrored in the rou-
tine reporting data for incident yaws cases, which showed a profound drop following mass
treatment with azithromycin. There was also a reduction in the prevalence of any ulcerative
skin lesion since our previous survey (6.0% vs 3.1%, p = 0.004). Taken together, these data sug-
gest that a single round of 20mg/kg azithromycin mass treatment given for trachoma may have
interrupted yaws transmission, resulting in a reduction of both prevalent and incident yaws
cases, and reducing the prevalence of skin lesions due to other bacteria.
Table 2. Risk factors for TPPA Positivity.
Variable Indicative prevalence data Unadjusted Odds Ratio 95% CI p-value
Age* 5–10: 21% 1.1 1.1–1.1 <0.001
11–14: 32%
Male Male: 27% 1.2 0.9–1.6 0.247
Female: 24%
Household size 5: 25% 1.0 0.8–1.4 0.836
>5: 26%
Reported taking Yes: 26% 0.9 0.6–1.3 0.598
azithromycin No: 24%
Household MDA Complete: 25% 0.8 0.5–1.4 0.472
Incomplete: 25%
None: 28% 0.9 0.5–1.3
*Risk associated with a 1 year increase in age
doi:10.1371/journal.pntd.0003988.t002
Fig 1. Prevalence of dual sero-positivity in individuals who did and did not receive treatment with azithromycin.
doi:10.1371/journal.pntd.0003988.g001
Impact of Trachoma MDA on Yaws
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003988 August 4, 2015 6 / 10
The results of this study are concordant with recently published data from Papua New
Guinea, which also demonstrated that a single round of azithromycin mass treatment, albeit at
a higher dose of 30mg/kg, significantly reduced the prevalence of active and latent yaws[19]. In
our study, effectiveness was demonstrated with a lower dose of azithromycin (20mg/kg), evi-
dence that facilitates integration of yaws control into national trachoma elimination plans. The
absence of any lesions which were positive by PCR for T. p subsp. pertenue is consistent with
the marked effect seen on serological markers of infection. Our failure to detect treponemal
DNA is somewhat reassuring in the context of the theoretical potential for lower dose azithro-
mycin to select for macrolide resistance[20]. Integrated, synergistic control efforts are likely to
result in increased efficiencies and decreased costs for programmes and ministries of health,
which will be vital in helping countries achieve elimination targets by 2020.
Table 3. Risk factors for dual sero-positivity.
Variable Indicative prevalence data Unadjusted Odds Ratio 95% CI p-value
Age 5–10: 3% 1.1 0.9–1.2 0.291
11–14: 4%
Male Male: 4% 1.4 0.7–2.8 0.394
Female: 3%
Household size 5: 4% 0.8 0.4–1.7 0.5980
>5: 3%
Reported taking azithromycin Yes: 2.8% 2.5 1.2–5.2 0.015
No: 6.7%
Household MDA Complete: 3.0% 0.097
Incomplete: 3.2% 1.1 0.5–2.6
None: 6.8% 2.4 0.9–5.7
doi:10.1371/journal.pntd.0003988.t003
Fig 2. Yaws clinical case reporting in Western Province, 2011–2014. The rainy season is indicated in
blue and the dry season in yellow. In the pre-mass treatment period there is evidence of seasonal variation in
the incidence of yaws, which is well recognized. Following mass treatment there was a profound drop in the
number of cases reported.
doi:10.1371/journal.pntd.0003988.g002
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In this population, individual level coverage with azithromycin was about 80%, which is in
line with that commonly achieved by trachoma elimination programmes. Our findings suggest
that an initial mass treatment round with high coverage can significantly reduce the burden of
infection. Whether subsequent treatment would be best delivered through community mass
treatment or the detection of cases and contacts remains unclear and should be studied further
using both observational and modeling approaches. In view of the extremely low positive pre-
dictive value of clinical signs for the diagnosis of yaws seen here, the call for point of care sero-
logical tests to be made available within the health care system[21] must be redoubled, in order
to strengthen surveillance and guide post-mass treatment case detection and treatment.
In trachoma control programmes in sub-Saharan Africa the use of height-based dosing
algorithms commonly results in children receiving doses of azithromycin closer to 30mg/kg
than 20mg/kg[22] which might make it difficult to detect meaningful differences in outcomes
between the two dosing strategies. As there were limited anthropometric data to guide
height-based dosing in the Pacific, weight-based dosing was used in the Solomon Islands,
and children therefore received a dose as close as possible to 20mg/kg body weight, to a maxi-
mum of 1g. This study therefore provides the first prospective data supporting the effective-
ness of lower dose azithromycin against yaws. This information is of particular value for
countries where yaws and trachoma are co-endemic and which may therefore benefit from
existing trachoma elimination activities.
The most notable limitation of this study is its observational nature. Whilst a randomized
design may have been desirable, this would have be unethical, given the need to implement
international guidelines for trachoma elimination[23], which mandate treatment of the whole
population. A stepped-wedge design could have been considered[24] but may have been uneth-
ical, for the same reason. Follow-up in this study was limited to 6 months, and it is possible
that longer observation would have revealed a more marked difference between the two groups.
We relied on reported receipt of azithromycin, which may have introduced an element of recall
bias. However it is likely that this would, in fact, have reduced any difference seen between
individuals who did and did not receive azithromycin, and therefore would not affect the over-
all finding of our study. RPR titres normally fall rapidly in individuals successfully treated for
yaws and, in the original randomized control trial of azithromycin conducted in Papua New
Guinea[5], combined clinical and serological cure was 96% at 6 months. It seems likely there-
fore that we have observed the greater part of the effect that might be expected to be derived
from azithromycin mass treatment.
Our findings support the roll out of mass treatment with azithromycin as an effective inter-
vention for the simultaneous elimination of trachoma and yaws in co-endemic areas, and pro-
vide further observational data to recommend the WHOMorges strategy where yaws alone is
endemic. The reduction in the prevalence of latent yaws following community mass treatment
is a particularly important result, as a failure to adequately treat these individuals is thought to
have contributed to the failure of previous yaws eradication efforts. Community mobilization,
ongoing surveillance and lasting political support will be necessary to translate these findings
into the ambitious goal of yaws eradication.
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